Severe and fatal forms of COVID-19 in children.
Adolescent
Betacoronavirus
/ isolation & purification
COVID-19
COVID-19 Testing
Child
Child, Preschool
Clinical Laboratory Techniques
Comorbidity
Coronavirus Infections
/ diagnosis
Disease Progression
Female
Humans
Infant
Male
Pandemics
Paris
/ epidemiology
Pneumonia, Viral
/ diagnosis
Prognosis
Retrospective Studies
Risk Factors
SARS-CoV-2
Severity of Illness Index
COVID-19
Coronavirus
SARS-Cov-2
Journal
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie
ISSN: 1769-664X
Titre abrégé: Arch Pediatr
Pays: France
ID NLM: 9421356
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
26
05
2020
accepted:
28
05
2020
pubmed:
11
6
2020
medline:
7
7
2020
entrez:
11
6
2020
Statut:
ppublish
Résumé
The aim of this study was to describe severe forms of novel coronavirus disease 2019 in children, including patient characteristics, clinical, laboratory, and imaging findings, as well as the disease management and outcomes. This was a retrospective, single-center, observational study conducted in a pediatric intensive and high-dependency care unit (PICU, HDU) in an urban hospital in Paris. All patients, aged from 1 month to 18 years, admitted for confirmed or highly suspected SARS-CoV-2 were included. We analyzed the data of 27 children. Comorbidities (n=19, 70%) were mainly neurological (n=7), respiratory, (n=4), or sickle cell disease (n=4). SARS-CoV-2 PCR results were positive in 24 children (nasopharyngeal swabs). The three remaining children had a chest CT scan consistent with COVID-19. Respiratory involvement was observed in 24 patients (89%). Supportive treatments were invasive mechanical ventilation (n=9), catecholamine (n=4), erythropheresis (n=4), renal replacement therapy (n=1), and extracorporeal membrane oxygenation (n=1). Five children died, of whom three were without past medical history. This study highlighted the large spectrum of clinical presentation and time course of disease progression as well as the non-negligible occurrence of pediatric life-threatening and fatal cases of COVID-19 mostly in patients with comorbidities. Additional laboratory investigations are needed to further analyze the mechanism underlying the variability of SARS-Cov-2 pathogenicity in children.
Identifiants
pubmed: 32518045
pii: S0929-693X(20)30117-2
doi: 10.1016/j.arcped.2020.05.010
pmc: PMC7269941
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
235-238Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.
Références
JAMA Pediatr. 2020 Apr 8;:
pubmed: 32267485
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Crit Care Med. 2013 Jul;41(7):1761-73
pubmed: 23685639
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
N Engl J Med. 2020 Jul 9;383(2):187-190
pubmed: 32356945
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
N Engl J Med. 2020 Apr 23;382(17):1663-1665
pubmed: 32187458
Pediatrics. 2020 Jun;145(6):
pubmed: 32179659
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Pediatr Crit Care Med. 2020 Jul;21(7):662-666
pubmed: 32265372
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
J Pediatric Infect Dis Soc. 2019 Mar 28;8(1):21-28
pubmed: 29447395
World J Pediatr. 2020 Jun;16(3):251-259
pubmed: 32193831
Lancet Respir Med. 2020 May;8(5):e35-e36
pubmed: 32304639
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143